Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model:: an additive effect of the combination

被引:26
作者
Firsov, AA
Vostrov, SN
Lubenko, IY
Portnoy, YA
Zinner, SH
机构
[1] Russian Acad Med Sci, Gause Inst New Antibiot, Dept Pharmacokinet & Pharmacodynam, Moscow 119021, Russia
[2] Russian Acad Med Sci, Inst Normal Physiol, Moscow 119021, Russia
[3] Harvard Univ, Sch Med, Mt Auburn Hosp, Cambridge, MA USA
关键词
moxifloxacin; doxycycline; resistance; in vitro models;
D O I
10.1016/j.ijantimicag.2003.11.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Twenty-four hour ratios of area under the curve (AUC(24)) to MIC of 200-240 h providing quinolone concentrations above the mutant prevention concentration (MPC) protected from enrichment of resistant Staphylococcus aureus in our recent study that simulated the pharmacokinetics of moxifloxacin, gatifloxacin, levofloxacin and ciprofloxacin. These protective AUC(24)/MICs might also be achieved by using antibiotic combinations, assuming additive effects of two anti-staphylococcal agents. To test this hypothesis, changes in S. aureus susceptibility were examined in a dynamic model that simulates 5-day treatment with moxifloxacin and doxycycline, alone and in combination at sub-optimal AUC(24)/MICs of each agent. Significant increases in MIC were observed with monotherapy where moxifloxacin or doxycycline concentrations fell into the mutant selection window (MSW) for more than 80% of the dosing interval (AUC(24)/MIC 60 h). Less pronounced changes in MIC occurred when the summed concentrations of moxifloxacin (AUC(24)/MIC 30 and 60 h) and doxycycline (AUC(24)/MIC 30 and 60 h) were inside the MSWs for the individual drugs for 30-50% of the dosing interval. No loss in susceptibility was found at moxifloxacin or doxycycline AUC(24)/MIC 170 h combined with the smaller AUC(24)/MIC (60 h) of the second compound. These data suggest that the total AUC(24)/MIC of 230 h might protect against S. aureus resistance. As this value is very close to that predicted in monotherapy with moxifloxacin (220 h), an additive protective effect of quinolone+doxycycline on the selection of resistant S. aureus is proposed. The use of drug combinations may be useful for restricting the enrichment of resistant mutants with agents whose clinically achievable AUC(24)/MICs do not provide concentrations above the MPC. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:451 / 456
页数:6
相关论文
共 10 条
[1]   INFLUENCE OF RANITIDINE, PIRENZEPINE, AND ALUMINUM MAGNESIUM-HYDROXIDE ON THE BIOAVAILABILITY OF VARIOUS ANTIBIOTICS, INCLUDING AMOXICILLIN, CEPHALEXIN, DOXYCYCLINE, AND AMOXICILLIN-CLAVULANIC ACID [J].
DEPPERMANN, KM ;
LODE, H ;
HOFFKEN, G ;
TSCHINK, G ;
KALZ, C ;
KOEPPE, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (11) :1901-1907
[2]   Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model [J].
FIRSOV, AA ;
CHERNYKH, VM ;
NAVASHIN, SM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (07) :1312-1317
[3]   Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model [J].
Firsov, AA ;
Vostrov, SN ;
Shevchenko, AA ;
Cornaglia, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1281-1287
[4]   Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept [J].
Firsov, AA ;
Shevchenko, AA ;
Vostrov, SN ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :659-665
[5]   In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus [J].
Firsov, AA ;
Vostrov, SN ;
Lubenko, IY ;
Drlica, K ;
Portnoy, YA ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1604-1613
[6]   PHARMACOKINETIC AND PHARMACODYNAMIC ACTIVITIES OF CIPROFLOXACIN AGAINST STRAINS OF STREPTOCOCCUS-PNEUMONIAE, STAPHYLOCOCCUS-AUREUS, AND PSEUDOMONAS-AERUGINOSA FOR WHICH MICS ARE SIMILAR [J].
HYATT, JM ;
NIX, DE ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2730-2737
[7]   Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model [J].
MacGowan, AP ;
Rogers, CA ;
Holt, HA ;
Bowker, KE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :1088-1095
[8]   Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects [J].
Stass, H ;
Dalhoff, A ;
Kubitza, D ;
Schühly, U .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2060-2065
[9]   Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies [J].
Zhao, XL ;
Drlica, K .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S147-S156
[10]   Restricting the selection of antibiotic-resistant mutant bacteria: Measurement and potential use of the mutant selection window [J].
Zhao, XL ;
Drlica, K .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (04) :561-565